Aprea Therapeutics, Inc. (APRE)

5.10 -0.16 (-2.95%) At close: 04:00PM EDT

Aprea Therapeutics, Inc.

3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Oren Gilad Ph.D.	Co-Founder, CEO, President & Director	796.95k	N/A	1968
Dr. Dansu Li Ph.D.	Head of Technology	N/A	N/A	N/A
Dr. Lars B. Abrahmsen Ph.D.	Senior VP & Chief Scientific Officer	N/A	N/A	1957
Mr. Brian Wiley	Senior Vice President of Corporate Development & Strategy	N/A	N/A	1968
Dr. Michel Afargan Ph.D.	Head of Pharmacology Development	N/A	N/A	N/A
Mr. Ze'ev Weiss B.Sc., C.P.A.	Chief Business Advisor	N/A	N/A	1962
Ms. Andrea Epstein	Controller	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Corporate Governance

Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.